• Recombinant Antibodies for In Vivo Research Launched

Laboratory Products

Recombinant Antibodies for In Vivo Research Launched

Absolute Antibody Ltd has announced the launch of its VivopureX™ recombinant mouse antibodies for in vivoresearch in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.

VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone’s original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralising antibodies in mouse models. As a result, the engineered recombinant antibodies offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts. In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.

All antibodies are produced recombinantly for ensured batch-to-batch reproducibility, and offer high purity and low endotoxin levels ideal for in vivo applications. The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40. Absolute Antibody data has shown that the recombinant mouse PD-1 antibody, based on the widely used clone RMP1-14, reduces tumour size in a mouse model more effectively than the original rat version.

“The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for in vivo researchers,” said Dr Michael Fiebig, Director of Products and Innovations at Absolute Antibody. “Most antibodies currently used in vivo are immunogenic, leading to adverse immunological reactions and gradual loss of activity. By applying the same protein engineering approaches used in therapeutic development to research reagents, we can improve in vivo research results and further our understanding into the mechanisms underlying immunotherapy.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

View all events